Abstract
We used pergolide to treat 10 patients with idiopathic Parkinson's disease who had first responded to, and then failed, bromocriptine therapy. At the end of 5 years, patients had improved when compared with study entry. Peak efficacy, equal with both drugs, was seen at 12 months. After a mean treatment of 29 months, bromocriptine was no longer effective, but pergolide was still beneficial.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antiparkinson Agents / adverse effects
-
Antiparkinson Agents / therapeutic use*
-
Bromocriptine / adverse effects
-
Bromocriptine / therapeutic use*
-
Drug Therapy, Combination
-
Dyskinesia, Drug-Induced / etiology
-
Dystonia / chemically induced
-
Ergolines / adverse effects
-
Ergolines / therapeutic use*
-
Female
-
Hallucinations / chemically induced
-
Humans
-
Levodopa / therapeutic use
-
Male
-
Middle Aged
-
Nausea / chemically induced
-
Outcome and Process Assessment, Health Care
-
Parkinson Disease / drug therapy*
-
Parkinson Disease / physiopathology
-
Pergolide
-
Time Factors
Substances
-
Antiparkinson Agents
-
Ergolines
-
Pergolide
-
Bromocriptine
-
Levodopa